focus -WSS

focus

author：knowledge 2025-10-02 08:24:20 - browse：9

Adobe

A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics. The deal is expected to net Akili’s shareholders $34 million.

Akili made headlines in 2020 when it received Food and Drug Administration clearance for EndeavorRx, a video game designed to treat pediatric ADHD. Akili went public in 2022 in a deal that valued the company at about $1 billion. But despite several strategic pivots, including shifting to direct-to-consumer sales, the company failed to build a sustainable business model. Akili in April announced it would wind down its existing commercial operations and focus on a licensing deal with Japanese pharma company Shionogi while it figured out the best path forward.

Akili is just one of many health tech companies that are struggling following an explosion of investor interest in digital health during the Covid-19 pandemic. In the last month alone, Better Therapeutics, another company making digital treatments, sold its assets for an undisclosed amount after failing to build a business around its app for type 2 diabetes, and Cue Health, a diagnostics startup, shut down after funding interest in its Covid-19 tests evaporated.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

knowledge

WSS

Dario to buy mental health app maker Twill in cash and stock deal

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Free speech concerns arise in wake of journal editor Eisen's firing

A clever new way to fix Medicaid and graduate medical education

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

entertainment

Walensky prepares to leave CDC — and Congress — behind

6 phony surgeries that take placebo to the extreme

Bright Health sells Medicare Advantage business to Molina

Ambulance rides for just $100? Advisers want major billing fixes

Continuity nursing helped my family in our darkest PICU moments

STAT readers on older presidents, polypills, Medicare, and more

At least 13 dead in Texas as scorching temps continue

Medicare inequities exacerbate Puerto Rico’s health disparities

BioMarin wins approval for gene therapy to treat hemophilia A

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

hotspot

New documents shed light on MD Anderson Cancer Institute feud

The Sacklers, horror, and ‘The Fall of the House of Usher’

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

With competition flaring, obesity drug hits goal in liver disease study

A solution to the after

R1 RCM gets $5.8 billion buyout offer from private equity firm

leisure time

knowledge

Wikipedia

focus